Research programme: CD91 receptor modulators - Agenus
Latest Information Update: 04 Nov 2017
At a glance
- Originator Antigenics
- Class Antibodies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 30 Aug 2006 This programme is still in active development
- 08 Apr 2002 Preclinical trials in Autoimmune disorders in USA (unspecified route)